| 1 |
32475902 | Efficacy and Safety of Miglitol- or Repaglinide-Based Combination Therapy with Alogliptin for Drug-Naïve Patients with Type 2 Diabetes: An Open-Label, Single-Center, Parallel, Randomized Controlled Pilot Study. | 2021 Mar 11 |
4 |
| 2 |
33716254 | Hypoglycemia during the Concomitant Use of Repaglinide and Clopidogrel in an Elderly Patient with Type 2 Diabetes and Severe Renal Insufficiency. | 2021 |
1 |
| 3 |
34939558 | A Review on Recent Controlled Release Strategies for Oral Drug Delivery of Repaglinide (a BCS Class II Drug). | 2021 |
1 |
| 4 |
32621047 | A time to revisit the two oldest prandial anti-diabetes agents: acarbose and repaglinide. | 2020 Nov |
1 |
| 5 |
33088647 | Severe hypoglycemia caused by a small dose of repaglinide and concurrent use of nilotinib and febuxostat in a patient with type 2 diabetes. | 2020 Oct |
2 |
| 6 |
30833929 | Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy. | 2019 |
1 |
| 7 |
31067468 | The Structural Basis for the Binding of Repaglinide to the Pancreatic KATP Channel. | 2019 May 7 |
2 |
| 8 |
31452966 | Interaction of repaglinide with bovine serum albumin: Spectroscopic and molecular docking approaches. | 2019 Aug |
2 |
| 9 |
30235745 | Characteristics of repaglinide and its mechanism of action on insulin secretion in patients with newly diagnosed type-2 diabetes mellitus. | 2018 Sep |
6 |
| 10 |
27967230 | PATHOPHYSIOLOGY AND MANAGEMENT OF HYPOGLYCEMIAIN END-STAGE RENAL DISEASE PATIENTS: A REVIEW. | 2017 Mar |
1 |
| 11 |
26692235 | Prolonged hypoglycemia after a suicidal ingestion of repaglinide with unexpected slow plasma elimination. | 2016 |
1 |
| 12 |
27857189 | A variation in KCNQ1 gene is associated with repaglinide efficacy on insulin resistance in Chinese Type 2 Diabetes Mellitus Patients. | 2016 Nov 18 |
4 |
| 13 |
25311380 | PPARD rs2016520 polymorphism affects repaglinide response in Chinese Han patients with type 2 diabetes mellitus. | 2015 Jan |
1 |
| 14 |
25560470 | Pharmacogenomics of glinides. | 2015 Jan |
2 |
| 15 |
26013675 | Insulin and other antidiabetic drugs and hepatocellular carcinoma risk: a nested case-control study based on Italian healthcare utilization databases. | 2015 Jul |
2 |
| 16 |
26024304 | A variant of PSMD6 is associated with the therapeutic efficacy of oral antidiabetic drugs in Chinese type 2 diabetes patients. | 2015 May 29 |
2 |
| 17 |
26548081 | Interaction of mouse intestinal P-glycoprotein with oral antidiabetic drugs and its inhibitors. | 2015 Sep |
1 |
| 18 |
24843581 | Efficacy and safety of repaglinide vs nateglinide for treatment of Japanese patients with type 2 diabetes mellitus. | 2012 Jun 6 |
1 |
| 19 |
21175273 | Effect of repaglinide versus glyburide on postprandial glucose and insulin values in elderly patients with type 2 diabetes. | 2011 Jan |
6 |
| 20 |
21362360 | Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in. | 2011 Jan |
2 |
| 21 |
21477042 | Glitazone-like action of glimepiride and glibenclamide in primary human adipocytes. | 2011 Sep |
1 |
| 22 |
21548456 | Hypersensitivity to repaglinide. | 2011 |
1 |
| 23 |
21835486 | Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus. | 2011 Nov |
4 |
| 24 |
20305679 | A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese. | 2010 Apr |
4 |
| 25 |
30861688 | Combination therapy for patients with Type 2 diabetes: repaglinide in combination with metformin. | 2010 May |
2 |
| 26 |
18777156 | Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control. | 2009 Mar |
5 |
| 27 |
19900993 | Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. | 2009 Nov 9 |
1 |
| 28 |
21437123 | Fixed combination of repaglinide and metformin in the management of type 2 diabetes. | 2009 Jun 24 |
1 |
| 29 |
18166815 | Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes. | 2008 Jan |
2 |
| 30 |
18621529 | Synthesis of hydantoin analogues of (2S,3R,4S)-4-hydroxyisoleucine with insulinotropic properties. | 2008 Aug 1 |
1 |
| 31 |
18664331 | Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients. | 2008 Aug |
1 |
| 32 |
17587398 | Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial. | 2007 Jul |
3 |
| 33 |
17953471 | Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review. | 2007 |
1 |
| 34 |
16475928 | Towards selective Kir6.2/SUR1 potassium channel openers, medicinal chemistry and therapeutic perspectives. | 2006 |
1 |
| 35 |
16539642 | Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. | 2006 Apr |
1 |
| 36 |
17211567 | Preprandial repaglinide decreases exogenous insulin requirements and HbA1c levels in type 2 diabetic patients taking intensive insulin treatment. | 2006 Dec |
5 |
| 37 |
15729954 | Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus. | 2005 Feb |
1 |
| 38 |
15855557 | Beta-cell response during a meal test: a comparative study of incremental doses of repaglinide in type 2 diabetic patients. | 2005 May |
3 |
| 39 |
15938025 | Oral antihyperglycemic agents and renal disease: new agents, new concepts. | 2005 Mar |
1 |
| 40 |
16142016 | Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. | 2005 Jun |
4 |
| 41 |
16176204 | Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes. | 2005 Oct |
6 |
| 42 |
20496449 | | 2005 May |
1 |
| 43 |
14715864 | The insulin secretagogues glibenclamide and repaglinide do not influence growth hormone secretion in humans but stimulate glucagon secretion during profound insulin deficiency. | 2004 Jan |
2 |
| 44 |
15099124 | Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. | 2004 |
2 |
| 45 |
15239026 | Enhancement of early- and late-phase insulin secretion and insulin sensitivity by the combination of repaglinide and metformin in type 2 diabetes mellitus. | 2004 Jul |
3 |
| 46 |
15334790 | Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application. | 2004 Jun |
1 |
| 47 |
15386823 | Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation. | 2004 Nov-Dec |
7 |
| 48 |
12817528 | Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. | 2003 Jun |
1 |
| 49 |
12919179 | CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. | 2003 Sep |
1 |
| 50 |
14614647 | Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. | 2003 Oct |
1 |